GPN’s Debt Load Is the Real Question in a $40B Buyout
The headline is seductive: Clayton, Dubilier & Rice, one of the largest private equity firms, is exploring a take-private of…
The headline is seductive: Clayton, Dubilier & Rice, one of the largest private equity firms, is exploring a take-private of…
An $85 million revenue surprise and 95% retention are forcing shorts to rethink 2026’s most punished ad-tech stock.
A note from our friends at Brownstone Research(ad) Dear Reader, My name is Jeff Brown, founder and CEO of Brownstone…
When a label change dents sentiment, not the franchise
Tonight’s Archer Aviation earnings call is a certification update wearing an earnings-report costume. Archer reports Q3 results after the close…
An independent investigation into Jensen Huang lands nine days before Q3 earnings, forcing institutional investors to price key-person risk.
A note from our friends at Weiss Ratings(ad) Dear Reader, A financial crisis usually doesn’t begin with one company defaulting…
A clean Phase 3 result puts Vir’s hepatitis delta drug on the path to a mid-2027 FDA filing, but Gilead is already approved and Mirum is right behind.
Applied Materials has never reported better numbers. Its stock has rarely looked worse. That gap closes Thursday. Sponsored NASA Is…
One undisclosed AI customer cut usage to its minimum commitment, and Wall Street punished the whole business for it.